Abstract
Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV encoded transgenes, raising the potential for their use in vaccine development. In this review, we have summarized current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.
Current Gene Therapy
Title: Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Volume: 2 Issue: 4
Author(s): J. Y. Sun, S. Chatterjee and K. K. Wong, Jr.
Affiliation:
Abstract: Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV encoded transgenes, raising the potential for their use in vaccine development. In this review, we have summarized current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.
Export Options
About this article
Cite this article as:
Sun Y. J., Chatterjee S. and Wong, Jr. K. K., Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347616
DOI https://dx.doi.org/10.2174/1566523023347616 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Polysaccharide Based Formulations for Mucosal Drug Delivery: A Review
Current Pharmaceutical Design Recent Patents on Cell Cycle Regulatory Proteins
Recent Patents on Biotechnology Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Coumarins as Antioxidants
Current Medicinal Chemistry Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Anticancer Drugs Aimed at E6 and E7 Activity in HPV-Positive Cervical Cancer
Current Cancer Drug Targets Lanthanum, Gallium and their Impact on Oxidative Stress
Current Medicinal Chemistry DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets Allergy and Inflammation: An Immunological and Therapeutic Approach
Recent Patents on Inflammation & Allergy Drug Discovery Gold Coordination Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
Current Drug Targets Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Advances in Vaccine Adjuvants For Infectious Diseases
Current HIV Research Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: Epigenetic Regulation and Human Diseases)
Current Pharmaceutical Design